XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Lessor Leases
 3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
Lessor Leases Lessor Leases
Sales-Type Leases
The Company enters into multi-year, sales-type lease agreements, with the majority of such leases varying in length from one to five years. The Company optimizes cash flows by selling a majority of its non-U.S. government sales-type leases, other than Advanced Services sales-type leases, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold. Some of the Company’s sales-type leases, mostly those relating to U.S. government hospitals which comprised approximately 31% of the lease receivable balance as of March 31, 2023, and those associated with financed service contracts related to certain Advanced Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, are retained in-house by the Company.
The following table presents the Company’s income recognized from sales-type leases for the three months ended March 31, 2023 and 2022:
Three Months Ended March 31,
20232022
(In thousands)
Sales-type lease revenues$5,716 $6,505 
Cost of sales-type lease revenues(2,662)(3,078)
Selling profit on sales-type lease revenues$3,054 $3,427 
The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at March 31, 2023 and December 31, 2022:
March 31,
2023		December 31,
2022
(In thousands)
Net minimum lease payments to be received$50,356 $50,755 
Less: Unearned interest income portion(6,559)(6,345)
Net investment in sales-type leases43,797 44,410 
Less: Current portion (1)
(11,053)(11,486)
Long-term investment in sales-type leases, net$32,744 $32,924 
_________________________________________________
(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.
The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.
The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows:
March 31,
2023
(In thousands)
Remaining nine months of 2023$9,810 
202410,710 
20258,707 
20267,073 
20275,627 
Thereafter8,429 
Total future minimum sales-type lease payments50,356 
Present value adjustment(6,559)
Total net investment in sales-type leases$43,797 
Operating Leases
The Company entered into certain leasing agreements that were classified as operating leases prior to the adoption of ASC 842, Leases. These agreements in place prior to January 1, 2019 continue to be treated as operating leases; however, any leasing agreements entered into on or after January 1, 2019 under these programs are classified and accounted for as sales-type leases in accordance with ASC 842. The operating lease arrangements generally have initial terms of one to seven years.
The following table represents the Company’s income recognized from operating leases for the three months ended March 31, 2023 and 2022:
Three Months Ended March 31,
20232022
(In thousands)
Rental income$2,259 $2,472 
Lessor Leases Lessor Leases
Sales-Type Leases
The Company enters into multi-year, sales-type lease agreements, with the majority of such leases varying in length from one to five years. The Company optimizes cash flows by selling a majority of its non-U.S. government sales-type leases, other than Advanced Services sales-type leases, to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold. Some of the Company’s sales-type leases, mostly those relating to U.S. government hospitals which comprised approximately 31% of the lease receivable balance as of March 31, 2023, and those associated with financed service contracts related to certain Advanced Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, are retained in-house by the Company.
The following table presents the Company’s income recognized from sales-type leases for the three months ended March 31, 2023 and 2022:
Three Months Ended March 31,
20232022
(In thousands)
Sales-type lease revenues$5,716 $6,505 
Cost of sales-type lease revenues(2,662)(3,078)
Selling profit on sales-type lease revenues$3,054 $3,427 
The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at March 31, 2023 and December 31, 2022:
March 31,
2023		December 31,
2022
(In thousands)
Net minimum lease payments to be received$50,356 $50,755 
Less: Unearned interest income portion(6,559)(6,345)
Net investment in sales-type leases43,797 44,410 
Less: Current portion (1)
(11,053)(11,486)
Long-term investment in sales-type leases, net$32,744 $32,924 
_________________________________________________
(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.
The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.
The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows:
March 31,
2023
(In thousands)
Remaining nine months of 2023$9,810 
202410,710 
20258,707 
20267,073 
20275,627 
Thereafter8,429 
Total future minimum sales-type lease payments50,356 
Present value adjustment(6,559)
Total net investment in sales-type leases$43,797 
Operating Leases
The Company entered into certain leasing agreements that were classified as operating leases prior to the adoption of ASC 842, Leases. These agreements in place prior to January 1, 2019 continue to be treated as operating leases; however, any leasing agreements entered into on or after January 1, 2019 under these programs are classified and accounted for as sales-type leases in accordance with ASC 842. The operating lease arrangements generally have initial terms of one to seven years.
The following table represents the Company’s income recognized from operating leases for the three months ended March 31, 2023 and 2022:
Three Months Ended March 31,
20232022
(In thousands)
Rental income$2,259 $2,472